Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante
(1, 2)
,
Remo Panaccione
(3)
,
Filip Baert
(4)
,
Peter Bossuyt
(5)
,
Jean-Frederic Colombel
(6)
,
Silvio Danese
(7, 8)
,
Marla Dubinsky
(6)
,
Brian Feagan
(9)
,
Tadakazu Hisamatsu
(10)
,
Allen Lim
(11)
,
James Lindsay
(12)
,
Edward Loftus
(13)
,
Julián Panés
(14, 15, 16)
,
Laurent Peyrin‐biroulet
(17, 18)
,
Zhihua Ran
(19)
,
David Rubin
(20)
,
William Sandborn
(21)
,
Stefan Schreiber
(22)
,
Ezequiel Neimark
(23)
,
Alexandra Song
(23)
,
Kristina Kligys
(23)
,
Yinuo Pang
(23)
,
Valerie Pivorunas
(23)
,
Sofie Berg
(23)
,
W Rachel Duan
(23)
,
Bidan Huang
(23)
,
Jasmina Kalabic
(24)
,
Xiaomei Liao
(23)
,
Anne Robinson
(23)
,
Kori Wallace
(23)
,
Geert d'Haens
(25)
1
University Hospitals Leuven [Leuven]
2 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
3 University of Calgary
4 AZ Delta
5 Imelda General Hospital
6 MSSM - Icahn School of Medicine at Mount Sinai [New York]
7 UniSR - Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie]
8 IRCCS Ospedale San Raffaele [Milan, Italy]
9 UWO - University of Western Ontario
10 Kyorin University School of Medicine [Tokyo, Japan]
11 University of Alberta
12 QMUL - Queen Mary University of London
13 Mayo Clinic [Rochester]
14 Clinic Barcelona Hospital Universitari
15 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
16 CIBERehd - Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas
17 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
18 Service d'Hépato-gastro-entérologie [CHRU Nancy]
19 Inflammatory Bowel Disease Research Center [Shanghai]
20 The University of Chicago Medicine [Chicago]
21 UC San Diego - University of California [San Diego]
22 CAU - Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel
23 Abbvie Inc. [North Chicago]
24 AbbVie Deutschland GmbH & Co KG
25 Amsterdam UMC - Amsterdam University Medical Center
2 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
3 University of Calgary
4 AZ Delta
5 Imelda General Hospital
6 MSSM - Icahn School of Medicine at Mount Sinai [New York]
7 UniSR - Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie]
8 IRCCS Ospedale San Raffaele [Milan, Italy]
9 UWO - University of Western Ontario
10 Kyorin University School of Medicine [Tokyo, Japan]
11 University of Alberta
12 QMUL - Queen Mary University of London
13 Mayo Clinic [Rochester]
14 Clinic Barcelona Hospital Universitari
15 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
16 CIBERehd - Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas
17 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
18 Service d'Hépato-gastro-entérologie [CHRU Nancy]
19 Inflammatory Bowel Disease Research Center [Shanghai]
20 The University of Chicago Medicine [Chicago]
21 UC San Diego - University of California [San Diego]
22 CAU - Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel
23 Abbvie Inc. [North Chicago]
24 AbbVie Deutschland GmbH & Co KG
25 Amsterdam UMC - Amsterdam University Medical Center
Laurent Peyrin‐biroulet
- Fonction : Auteur
- PersonId : 1111110
- ORCID : 0000-0003-2536-6618
- IdRef : 087640147
Résumé
There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody, was efficacious and well tolerated as induction therapy. Here, we report the efficacy and safety of subcutaneous risankizumab as maintenance therapy.
AbbVie.